<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04761705</url>
  </required_header>
  <id_info>
    <org_study_id>JV-GL1-OCU-GL-101/201-01</org_study_id>
    <nct_id>NCT04761705</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of JV-GL1 in Patients With Open-Angle Glaucoma or Ocular Hypertension</brief_title>
  <official_title>A Phase 1/2 Safety and Efficacy Study of JV-GL1 Applied to the Periorbital Skin in Subjects With Open-Angle Glaucoma or Ocular Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JeniVision, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>JeniVision, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this research study is to assess the safety and feasibility of lowering&#xD;
      intraocular pressure (IOP) using an experimental study drug, JV-GL1.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, dose escalation and dose expansion, study in adult participants with&#xD;
      open-angle glaucoma or ocular hypertension. The study is divided into 2 parts:&#xD;
&#xD;
      Part 1 of the study is a dose escalation, sequentially testing 3 doses of JV-GL1: low, medium&#xD;
      and high.&#xD;
&#xD;
      Part 2 of the study will be randomized 2:2:1 (Experimental Dose A: Experimental Dose B:&#xD;
      Active Control), treating additional subjects at the selected JV-GL1 doses or Latanoprost for&#xD;
      28 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 10, 2021</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraocular Pressure (IOP)</measure>
    <time_frame>From Baseline to Day 28 of Treatment</time_frame>
    <description>Change from baseline in Intraocular Pressure (IOP)</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Ocular Hypertension</condition>
  <condition>Open Angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>Randomized Part 2, Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 1 selected in Part I</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Randomized Part 2, Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 2 selected in Part I</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Randomized Part 2, Arm 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JV-GL1</intervention_name>
    <description>Experimental Treatment</description>
    <arm_group_label>Randomized Part 2, Arm 1</arm_group_label>
    <arm_group_label>Randomized Part 2, Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Latanoprost 0.005% Ophthalmic Solution</intervention_name>
    <description>Active Control</description>
    <arm_group_label>Randomized Part 2, Arm 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  bilateral open-angle glaucoma or ocular hypertension&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Wirta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eye Research Foundation, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Wirta, MD</last_name>
    <phone>949-650-1863</phone>
    <email>info@drwirta.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Eye Research Foundation</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Wirta, MD</last_name>
      <phone>949-650-1863</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 16, 2021</study_first_submitted>
  <study_first_submitted_qc>February 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>March 22, 2021</last_update_submitted>
  <last_update_submitted_qc>March 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>open angle glaucoma</keyword>
  <keyword>Ocular Hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Latanoprost</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

